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Aims To investigate the efﬁcacy of preventive and antitachycardia pacing (ATP) in patients with
symptomatic paroxysmal atrial ﬁbrillation (AF) without bradyarrhythmias.
Methods and results In this randomized cross-over pilot study, we randomized 38 symptomatic parox-
ysmal AF patients ‘without’ bradyarrhythmias to atrial pacing lower rate 70 ppm and prevention and ATP
therapies ON or to atrial pacing lower rate 34 ppm and prevention and ATP therapies OFF during 12
weeks with a 4 week washout period in between. The atrial lead was preferably placed in the inter-
atrial septum. Antiarrhythmic drugs were continued during the study. Primary endpoint was AF
burden. Mean age was 62+9 years and 27 (71%) patients had lone AF. Septal lead placement was
accomplished in 26 (68%) patients. During the treatment ON, there was a trend for AF burden reduction
[from median 3.3% (1.0–15.2) to 2.4% (0.2–12.2), P ¼ 0.06, reduction 27%]. If septal lead placement
was accomplished, AF burden reduction was statistically signiﬁcant [44% reduction, from median 2.5%
(1.0–8.0) to 1.4% (0.2–8.4), P ¼ 0.03]. Quality of life and symptoms did not change, also not in the
septal group.
Conclusion A hybrid therapy of preventive and ATP pacing and antiarrhythmic drugs may signiﬁcantly








Rate control is an accepted primary treatment strategy in
atrial ﬁbrillation (AF),1,2 especially in the presence of under-
lying heart disease.3 Rhythm control, however, remains
therapy of choice in patients suffering from symptomatic
AF.4 The cornerstone for rhythm-control therapy is serial
antiarrhythmic drug treatment with or without cardiover-
sions. This strategy often fails.5 Transvenous catheter abla-
tion of the left atrium is nowadays the ﬁrst choice in
therapy if antiarrhythmic drug therapy fails.6–10 Success,
i.e. long-term maintenance of sinus rhythm can be
accomplished in up to 70–90% of patients, but severe com-
plications occur.11 Recurrent AF, thereafter, may happen
asymptomatically overestimating the success rate.12–14 The
role that pacing therapies play in the prevention of AF
remains unclear. Multiple randomized trials have demon-
strated that atrial single- or dual-chamber pacing may
prevent AF in patients with symptomatic bradycardia as
primary pacing indication, especially in patients with sinus
node dysfunction.15 The efﬁcacy of atrial preventive
pacing therapies in patients ’without’ symptomatic brady-
cardia is still uncertain,16–19 as is the inﬂuence of speciﬁc
atrial pacing sites.17,20–23 The AT500
TM
, a DDDRP-pacemaker
(Medtronic Inc, Minneapolis), has additional preventive and
termination pacing therapies that may reduce AF burden* Corresponding author. Tel: þ31 50 361 1327; fax: þ31 50 361 4391.E-mail address: i.c.van.gelder@thorax.umcg.nl
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and improve quality of life in patients with symptomatic AF.
The primary objective of the present randomized pilot study
was to investigate to what extent atrial prevention and ter-
mination pacing therapies of AT500
TM
compared to no active
treatment (AAI 34 ppm backup pacing) can reduce AF burden
in patients with symptomatic AF without bradyarrhythmias.
Secondary objectives were to investigate the patients’
quality of life and symptoms.
Methods
Study design
Seven centres in the Netherlands participated in this randomized,
single blind, cross-over pilot study (see Appendix). All patients
gave their written informed consent. The institutional review
boards of all hospitals approved the protocol. The study started in
June 2004. Total follow-up was 36 weeks in all patients. The study
ended in November 2005.
Patients between 18 and 70 years of age with documented
paroxysmal AF, who had at least three symptomatic episodes of
30 min during the previous 3 months, and who failed on at least
two different antiarrhythmic drugs (of which at least one belonged
to Class IC or III) were included in the study. Exclusion criteria were
bradyarrhythmias necessitating pacing (sick sinus node or atrioven-
tricular node disease), presence of clinically signiﬁcant valve
disease, unstable angina pectoris, untreated coronary artery
disease or hypertension (systolic tension .160 mmHg and/or dias-
tolic tension .95 mmHg), advanced chronic heart failure NYHA III
or IV, thyroid disorders, malignancy, and alcohol or drug abuse.
Pacemaker features—atrial tachycardia/atrial
ﬁbrillation prevention and termination algorithms
Patients received an AT500
TM
(DDDRP-pacemaker, Medtronic Inc.)
with two bipolar leads. The atrial lead, with a tip-ring distance of
a maximum of 12 mm, was preferably positioned in the inter-atrial
septum. In the case of signiﬁcant far-ﬁeld R-wave oversensing (i.e.
detected by the device) or in the case that no adequate position
could be obtained in the inter-atrial septum, the atrial lead was
positioned in the right atrial lateral wall or right atrial appendage.
The ventricular lead was positioned in the right ventricular apex,
but ventricular pacing was never performed during the study.
The device distinguishes between AF and atrial tachycardia (AT)
using (i) the P–P interval length (see below) and (ii) the dual
chamber rhythm pattern information which can discriminate
between far-ﬁeld R-wave oversensing and sinus tachycardia from
atrial arrhythmias. During the entire study period, the AF detection
zone was programmed between 100 and 200 ms (600–300 bpm) and
the AT detection zone between 160 and 350 ms (375–171 bpm). To
ensure accurate atrial arrhythmia detection, an atrial threshold
25% of the telemetered P-wave .0.2 mV was provided, resulting
in a sensitivity of 0.45 mV. Both AF and AT episodes contribute
to the AF burden. The latest 35 episodes were stored in the
episode storage log, but the AF burden was calculated from all AT
and AF episodes during a study period.24 The DDDRP-device offers
the following preventive and termination pacing therapies, as has
been previously described:24 (i) atrial preference pacing (APP), an
atrial overdrive algorithm which dynamically sets the pacing rate
just above the intrinsic rate. In the present study, after an intrinsic
atrial event the pacing interval was decreased with 50 ms up to a
minimum of 600 ms. After each 10 consecutive paced beats, the
interval was increased again with 20 ms; (ii) atrial rate stabilization
(ARS), an atrial pacing therapy designed to inhibit the onset of atrial
arrhythmias by eliminating the long pause that typically follows a
premature atrial contraction. It is a programmable feature that
resets each atrial escape interval by multiplying the last PP interval
by an increment of, in the present study, 25%. In this way after a
premature atrial complex, the atrial rate gradually returns to the
intrinsic or programmed rate; and (iii) post mode switch overdrive
pacing (PMOP) to prevent immediate recurrences of AF after an
AF episode has stopped by transiently pacing at a higher rate, e.g.
90 bpm for 10 min.25,26 Since all our patients were paced in the
AAI mode and in this setting the device does not switch mode,
the PMOP feature was not be enabled in this study. In addition, the
antitachycardia pacing (ATP) termination algorithm was used,
which can detect and terminate a fast atrial rhythm, which not
rarely is the onset of AF.27 ATP is analogous to the pacing tech-
niques used to terminate ventricular tachycardias by pacing.
There are two automatic pacing strategies, Ramp and Burstþ,
which aim to capture the atrium during a tachyarrhythmia and
are able to terminate the abnormal rhythm. ATP was programmed
as follows in the present study: (i) 10 Ramp sequences starting at
88% of the AT cycle length (the average of the last four P–P inter-
vals prior to detection) for a total of 10 pulses with a decrement of
the cycle length of each pulse with 10 ms; (ii) if unsuccessful 10
Burstþ sequences, starting at 84% of the AT cycle length, second
sequence with an interval of 75% of the AT cycle length, for a
total of 10 pulses with a decrement of cycle length of each pulse
with 10 ms, and ﬁnally (iii) 10 Ramp sequences starting at 81% of
the AT cycle length for a total of 10 pulses with a decrement of
cycle length of each pulse with 10 ms. ATP will only occur when
the device deﬁnes the atrial arrhythmia as AT, not when it recog-
nizes AF. ATP is considered successful if sinus rhythm has been
restored for at least ﬁve consecutive sinus beats.
Study protocol
Figure 1 shows the study ﬂow-chart. During the 4 weeks run-in
period, echocardiography was used to assess underlying heart
disease, exercise testing to exclude coronary artery disease and
24 h Holter monitoring was performed to exclude persistent or per-
manent AF. Antiarrhythmic drugs were allowed but patients had to
be on stable antiarrhythmic therapy for at least 8 weeks before
they were randomized. Daily record card data were collected
from the run-in period to assess the proper recording of AF
related symptoms (see below). Patients were not randomized if no
proper recording of symptoms on the diary cards was conﬁrmed.
After this run-in period, an AT500
TM
pacemaker was implanted.
During the ﬁrst 4 weeks after implantation and in between the
two treatment periods, i.e. from 12 to 16 weeks after randomiz-
ation, all AT/AF prevention and termination features were pro-
grammed to ‘OFF’ in both groups. The purpose of the ﬁrst period
is to allow lead ﬁxation and stabilization of the patient’s atrial
tachyarrhythmia since these might be induced by the implant pro-
cedure. The purpose of the second period, i.e. from 12 to 16
weeks after randomization, is to prevent a carry-over effect from
the ﬁrst study period to the second study period. One month after
implantation, all patients meeting the randomization criteria were
Figure 1 Study ﬂow-chart.
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randomized to either Group A or Group B. In Group A APP, ARS, and
ATP were programmed to ‘ON’ and the lower rate was set at 70 ppm
from 0 to 12 weeks after randomization. In Group B, these features
were programmed ‘ON’ from 16 to 28 weeks after randomization.
During the remaining time, APP and ARS were programmed ‘OFF’
and the lower rate was set at 34 ppm (Figure 1). During the ‘OFF’
period a ‘dummy-programming’ was done. This means that an
ineffective (fake) ATP (1 pulse at 1 V during 0.03 ms at 97% of the
current AA interval) was programmed in order to obtain similar
episode information in both groups. In order to prevent bradycardia
induced AF we choose a lower rate of 70 ppm during the ON period.
To avoid pacing as much as possible the lowest possible pacing rate
(34 ppm) was programmed during the OFF period.
Quality of life and symptoms
The quality of life was assessed using the Medical Outcomes Study
Short-Form health survey (SF-36).28 The SF-36 is a standardized,
validated and generic health survey that has been frequently used
in arrhythmia studies. The SF-36 has been translated and validated
in the Netherlands.29 It contains items to assess physical health
(general health perception, physical functioning, role limitations
due to physical problems, and bodily pain) and mental health
(social functioning, role limitations due to emotional problems,
mental health and vitality). In addition, a healthy, age-matched
control group was selected from Dutch subjects who served to vali-
date the Dutch version of the SF-36. Symptoms related to AF were
assessed by means of diary cards and by the Symptom Checklist—
Frequency and Severity Scale. The latter was developed as disease-
speciﬁc instrument intended to measure the patient’s perception of
the frequency and severity of arrhythmia-related symptoms.30 The
instrument has been demonstrated to be valid for the use in patients
with persistent or paroxysmal AF. For each of 16 symptoms, patients
assigned numerical scores (0–4 for frequency and 0–3 for severity).
The overall possible scores are 0–64 (0 ¼ never, 64 ¼ always) for
frequency and 0–48 for severity. Symptoms were also assessed on
a daily basis using diary cards. Every day patients assessed to
what extent he or she suffered from fatigue, palpitations,
dyspnea, dizziness, and chest pain (1,none; 2, a little/mild; 3, mod-
erate; 4, severe; 5, extreme). Severity of fatigue was measured at
the same moments as quality of life with the multidimensional
fatigue index (MFI-20).31 Patients were asked to ﬁll in all question-
naires at home within 3 days after the screening visit and all other
study visits. Daily record card data were collected from the run-in
period to assess the proper recording of AF related symptoms.
Patients were not randomized if no proper recording of symptoms
on the diary cards was conﬁrmed.
Deﬁnitions
AF burden was deﬁned as the time the patient was in AT/AF divided
by the total treatment time. The AF burden was calculated from all
AT and AF episodes during a study period (e.g. run-in phase, ON
period, as measured by the device).
Statistical analysis
For this pilot study, no formal sample size calculations were per-
formed. The primary outcome parameter was the reduction of AF
burden. To evaluate the efﬁcacy of atrial pacing (AAI 70 ppm, ARS
and APP) and ATP using the AT500
TM
on the AF burden we used a
Wilcoxon test for paired samples, as the AF burden was not normally
distributed. In addition, the AF burden was dichotomized and con-
ditional logistic regression was used to evaluate the presence of
an AF burden below and above the median AF burden (41 min). In
this analysis, treatment as well as the sequence, period and patients
within the sequence were included, to account for carry-over effect
and treatment by period interaction. The same methods were used
for the secondary outcome parameters. A two way cross-over analy-
sis of variance was used for continuous data. Baseline and results
descriptive statistics are given as the mean+SD or median (inter-
quartile range) for continuous variables and counts with percen-
tages for categorical variables. Commercially available computer
software (Statistical Analysis System version 9.1, SAS Institute,
Cary, North Carolina) was used for all analyses.
Results
Characteristics of patients
A total of 52 patients were enrolled in the study. Pacemakers
were not implanted in two patients because one of them
developed persistent AF and the other improved on amio-
darone. One patient was withdrawn from the study prior
to the planned implantation due to clinically signiﬁcant
atrioventricular nodal conduction disturbances necessitating
pacemaker implantation. After the successful implantation,
11 other patients were not randomized because of the
development of persistent AF (n ¼ 5), bradycardia necessi-
tating pacing (n ¼ 4), and refusal to participate further
(n ¼ 2). The remaining 38 patients were randomized and
treated according to the protocol (Figure 1). Baseline
characteristics are depicted in Table 1. Median number of
AF episodes during the last 3 months before inclusion was
24 (range 9–90), median duration 2.5 h (1.0–10.8). Thirty
patients (79%) were in Class I and/or Class III antiarrhythmic
drugs and continued these drugs throughout the study.
Septal lead placement was accomplished in 26 patients
and failed in 12 patients (no stable septal positioning,
n ¼ 6, and signiﬁcant far-ﬁeld R-wave sensing, n ¼ 6).
Accordingly, the atrial lead was placed in the free lateral
wall (6 patients) or right atrial appendage (6 patients).
There were no differences in baseline characteristics
between the patients with septal and non-septal lead
placement.
Atrial pacing and atrial ﬁbrillation burden
During the OFF and ON periods, atrial pacing was 0% and 98
(93–99)%, respectively, both for the total and septal group.
The median AF burden during the run-in phase was 2.8 (0.5–
28.7)% in the total group. The median daily AF burden fell
from 3.3 (1.0–15.2)% to 2.4 (0.2–12.2)%, P ¼ 0.06 (Figure
2A), a reduction of 27% during active treatment (ON
phases). This means a reduction from a median of 48 (14–
219) to 35 (3–176) min per day. During the run-in phase in
six patients (16%) no AF occurred, and during the ON and
OFF periods, seven (18%) and four patients (11%) were free
from AF episodes, respectively (P ¼ NS). One patient devel-
oped persistent AF during the ﬁrst study period (OFF period)
and discontinued the study after this period. In the subgroup
of 26 patients with septal lead placement, the AF burden
fell during pacing therapy from a daily median AF burden
from 2.5 (1.0–8.0)% to 1.4 (0.2–8.4)%, P ¼ 0.03 (Figure
2B), a reduction of 44%, i.e. from 36 (14–115) to 20 (3–
121) min per day. During the run-in ON and OFF period,
respectively, 5 (19%), 6 (23%) and two patients (8%) were
free from AF episodes, P ¼ NS. Conditional logistic
regression analysis, after dichotomization of the AF burden
during the run-in phase (median AF burden 2.8%, i.e.
41 min), showed a comparable result without evidence of
carry-over effect. However, there was a trend for a period
effect (P ¼ 0.06): therapy ON during the ﬁrst period was
borderline signiﬁcantly more effective as compared to
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therapy ON during the last period (Figure 3A and B). Time to
ﬁrst recurrence was not different between the groups: a
median of 1 (1–5) vs. 3 (1–12) days in the ON vs. OFF
group, respectively, also not in the patients with septal
lead placement. During follow-up six and ﬁve patients in
the ON and OFF group, respectively, did not have any recur-
rence of AF. The individual responses are depicted in Figure
4A and B. Mean efﬁcacy of ATP during active treatment was
57+30% and during the OFF period (dummy) ATP was effec-
tive in 24+19%, P , 0.05. During the ON period, the ATP
efﬁcacy was 61+27% vs. 48+37% in the septal vs. non-
septal group, respectively, P ¼ NS.
Quality of life, symptoms, and fatigue index
The quality of life at study entry was lower for our patients
compared to a healthy age- and sex-matched control group
for physical role limitations, social functioning, and vitality
(Figure 5). Comparing quality of life during the ON and
OFF period, only mental health was signiﬁcantly higher
during the ON period, indicating a better quality of life on
this subscale (data not shown). Comparable data were
found in patients with septal lead placement. Analysis of
the symptom checklist revealed no changes, neither in
symptom frequency and symptom severity nor in number
of symptoms during the OFF and ON periods (Table 2). Also
daily complaints were comparable. Fatigue and palpitations
were the most frequently recorded symptoms during the
study (Figure 6). Whereas palpitations predominantly
occurred during the days of AF, fatigue was also present at
the ﬁrst days after an AF episode (Figure 7). Comparison
of the daily symptoms scores with the days on which AT or
AF occurred (device data) revealed that 23% of the AT/AF
episodes were completely asymptomatic, 45% of AT/AF
periods slightly symptomatic, and 32% of AT/AF periods
moderate to severely symptomatic. The multidimensional
fatigue index also showed no signiﬁcant changes comparing
the OFF and ON periods (Table 3).
Cardioversions and antiarrhythmic drugs
During the ON and OFF period, one and four electrical cardi-
oversions were performed, respectively, in a total of three
patients. No chemical cardioversions were performed.
There were no changes in antiarrhythmic drugs during
active treatment, while during the OFF period the




Mean age (years) 62+9
Male gender—number of patients (%) 20 (53)
History of paroxysmal AF—years 7.1+5.4
Number symptomatic PAF episodes (last 3
months)
24 (9–90)
Duration symptomatic PAF episodes (last 3
months, hours per episode)
2.5 (1.0–10.8)
History of hypertension—number of
patients (%)
10 (26)
Old myocardial infarction—number of
patients (%)
1 (3)
No apparent heart disease—number of
patients (%)
27 (71)
Heart failure—number of patients (%)
NYHA I 35 (92)




















ACE, angiotensin converting enzyme; ARB, angiotensin receptor
blocker; LVEDD, left ventricular end diastolic diameter; LVESD, left ven-
tricular end systolic diameter; NYHA, New York Heart Association class
for heart failure; aTwo patients used ﬂecainide in combination with
sotalol.
Figure 2 Difference in median AF burden between no treatment
(OFF period) and active treatment (ON period), in all patients
(n ¼ 38, A) and in the septally paced patients (n ¼ 26, B).
Right atrial preventive and antitachycardia pacing 309
amiodarone dose was increased (from 200 to 400 mg daily
for 4 weeks) in two patients and metoprolol was started in
one patient for rate control.
Discussion
This pilot study shows that a hybrid therapy of preventive
and ATP pacing and antiarrhythmic drugs in patients with
severely symptomatic AF ‘without’ bradycardia may
reduce but not abolish AF burden if septal pacing is realized.
However, the patients’ quality of life and symptoms do not
improve.
Rhythm control remains indicated in patients suffering
from symptomatic AF.4 Antiarrhythmic drug therapy with
or without cardioversion is only moderately effective.5
Atrial catheter ablation is nowadays a ﬁrst choice therapy
for refractory symptomatic patients.6–10 Even before the
widespread use of atrial ablation, pacing with or without
preventive and antitachycardia features was studied for its
value to prevent AF. Previous studies with atrial pacing
alone instead of ventricular-based pacing15,16,32–37 have sup-
ported the idea that atrial pacing may prevent or reduce AF.
Prevention of AF by atrial pacing, especially in the presence
of sick sinus syndrome has been demonstrated to be ben-
eﬁcial.15,32–34,36,37 The magnitude of its beneﬁt, however,
is only modest. Other pacing methods have therefore been
evaluated. These include alternate site pacing, multisite
pacing, overdrive pacing, and various preventive and ter-
mination pacing algorithms.17,19–24,38–41 Up to now, studies
on the additional value of preventive and termination
pacing therapies have not been conclusive,24,38,42–44 and
only a limited number of studies have investigated this
issue in patients without a bradycardia indication for
pacing.16–19 The present study shows a trend for AF burden
reduction during active treatment, that was signiﬁcant in
the subgroup of patients with septal lead placement.
However, the patients’ quality of life and symptoms did
not signiﬁcantly change.
Figure 4 Individual AF burden during the OFF and ON period in the
total (A) and septal (B) group.
Figure 3 AF burden during each study phase (monitor and washout
phase [white], ON period [gray], and OFF period [black]) according
to randomization groups in all patients (Group A [n ¼ 19] and Group
B [n ¼ 19], A) and in the septal paced patients (Group A [n ¼ 12] and
Group B [n ¼ 14], B). Note that in group A the ON period (grey) was
during the ﬁrst study period after the monitor phase vs. the last
study period after the washout phase in Group B.
Figure 5 Differences in quality of life subscales between the total
group at baseline vs. age- and sex-matched healthy controls. *P ,
0.05.
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Importantly, septal pacing seems more effective than
pacing at more conventional sites. Previous studies demon-
strated that septal pacing, and also dual site right atrial
and biatrial pacing shorten total atrial activation time and
reduce overall dispersion of atrial refractoriness.45 In
addition, clinical studies suggest that atrial septal lead pla-
cement is superior in preventing AF.23,46 Therefore, in this
study, atrial septal lead placement was chosen as the pre-
ferred pacing site but it was not mandatory. Septal pacing
was accomplished in 68% of patients. In accordance with
previous data, our study demonstrates a better outcome
for these patients. As the study was not designed to assess
the efﬁcacy of septal pacing no deﬁnite conclusions can be
drawn from this ﬁnding. Furthermore, although AF burden
reduction was signiﬁcant, this was not accompanied by
improvement in quality of life and symptom scores. This
may be explained by the fact that the AF burden reduction
reached statistical signiﬁcance, but was not clinically rel-
evant: AF burden was reduced but not abolished. Despite
therapy, in more than half of the patients, AF still occurred
during 2.5% of the time, which was obviously noticed by
the patients. Unfortunately, in 32% of septal lead placement
failed either because no stable septal positioning could be
reached or signiﬁcant far-ﬁeld R-wave sensing was
present. This low success rate may, on one hand, relate to
insufﬁcient investigators’ experience, on the other hand to
the well known problem of far ﬁeld R-wave oversensing if
this lead position is attempted.47,48
Why may atrial preventive pacing be effective? First, it
may prevent triggers, i.e. atrial premature complexes, bra-
dycardia, and ATs.49 Secondly, it may alter the substrate,
i.e. prevent dispersion in conduction velocity and atrial
effective refractory periods. Additionally, the presently
used device offers ATP that was effective in 57% of episodes.
In the TREAT study, which also showed success of atrial
pacing in drug refractory paroxysmal AF patients without
bradycardia indication for pacing, ATP efﬁcacy was about
comparable: 52+28%.50 However, also during the OFF
period ATP was effective in 24+19% of the episodes. This
suggests that part of the ATP-efﬁcacy relates to spontaneous
termination of AF during ATP. From the present data,
however, we cannot conclude whether AF burden reduction
was due to either the effectiveness of ATP therapy or due to
the combination of ATP therapy and preventative pacing as
both therapies were activated during the treatment
ON periods. As septal pacing was most effective, shortening
of total atrial activation time and reduction of dispersion
of atrial refractoriness and conduction velocity, i.e.
modiﬁcation of the substrate, seems essential.
At baseline, quality of life was importantly reduced
compared to the age and sex-matched healthy controls.
Table 3 Multidimensional Fatigue Index (MFI-20) scores during
the OFF vs. the ON period
MFI-scales OFF period ON period
General fatigue 11+4 12+4
Physical fatigue 10+4 10+4
Reduced activity 10+4 10+4
Reduced motivation 9+3 9+4
Mental fatigue 9+4 8+4
Figure 7 Percentage of patients with palpitations (A) and fatigue
(B) in the total group the day before AF, at the day of (an) AF epi-
sode(s) and the days after that AF episode(s). *P , 0.05 in compari-
son with the day before and the days after.
Table 2 Symptom checklist scores (mean+SD) during the OFF
vs. ON period
OFF period ON period
Symptom frequency score 17+10 16+8
Symptom severity score 12+7 12+8
Number of symptoms 10+4 10+4
Figure 6 AF related daily symptom scores during the OFF vs. ON
phase. Percentage of days with symptoms is presented.
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Nevertheless, despite a reduction in the AF burden, we
observed no change in the quality of life, nor in the severity
and frequency of symptoms, nor in fatigue. On one hand,
this may be explained by the fact that the observed
reduction in the AF burden, also in the septal lead place-
ment group, was too small to improve the quality of life.
On the other hand, pacing with a lower rate of 70 ppm in
combination with preventive and termination pacing thera-
pies may have offset the beneﬁcial effects of the AF burden
reduction.
Finally, one of our ﬁndings may be of clinical signiﬁcance.
Although palpitations were only present on the day of a
symptomatic AF episode, fatigue was also present during
the ﬁrst 2 days thereafter. Indeed, AF patients always com-
plain about fatigue outlasting the AF episode in which their
social environment does not always understand. The present
data may add to the understanding that AF may also
severely impair physical and social activities beyond an AF
paroxysm.
Limitations
A limited number of patients have been included in this pilot
study. This precludes deﬁnite conclusions, but it may be
used to generate hypotheses. Possibly, if more patients
were randomized and septal lead position was achieved in
a higher percentage of patients, the outcome might have
been different, also for the quality of life results. On the
other hand, to assess the efﬁcacy of atrial septal pacing,
the latter must be a prerequisite. This requires further
study. In addition, in studies like ours, AF burden is not nor-
mally distributed and usually shows a high spontaneous
inter- and intra-patient variability, which has a negative
impact on statistical power and impairs the ability to ident-
ify patients as responders or non-responders.51,52 Even
patients with a very low AF burden were included that
may have further affected the outcome negatively. We
used a 1 month washout period between treatment
periods in this cross-over study design in order to combat
the possible effects of ongoing atrial remodelling impairing
the outcome of the patients who were ﬁrst randomized to
have the therapy ‘OFF’. Nevertheless, we observed a
trend for a period effect.
Conclusions
The present pilot study, albeit small, suggests that the
pacing in AF may signiﬁcantly reduce the AF burden.
However, it did not reveal a clinically relevant effect on
the patients’ quality of life and the reduction of symptoms.
Accordingly, we conclude that atrial pacing should not be
considered a ﬁrst choice therapy in patients with sympto-
matic AF ‘without’ bradyarrhythmias. Although it requires
further study, atrial pacing seems to be most effective if
septal pacing is realized. This may have future signiﬁcance,
probably also in heart failure patients treated with cardiac
resynchronization as compensation for the long inter-atrial
conduction delay. Whether additional preventive pacing
and termination therapies offer additional value is currently
being investigated in the Study of Atrial Fibrillation
Reduction (SAFARI).53
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